Login
$EIKN
$5.39 -$0.60 (9.95%) Live

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Source
Roger M. Perlmutter Also a director
Chief Executive Officer, Chair and Director
73 Since 2021
5 years
Alfred Bowie
Chief Financial Officer
44 Since 2021
5 years
Michael Klobuchar
Chief Operating Officer
50 Since 2024
2 years
Roy Baynes
Executive Vice President and Chief Medical Officer
71 Since 2022
4 years
Benjamin Thorner
Chief Business Officer and General Counsel
55 Since 2021
5 years

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the 10-K annual report · updated by the 8-Ks of Jun 10, 2026 and Aug 3, 2026

Directors
5
serving now
Independent
3 of 4
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
Yes
Roger M. Perlmutter
Director Age On board Independent Committees Other public boards Pay Source
Roger M. Perlmutter
73 2021
5 years
Not independent None stated Insitro, Inc., NGM Biopharmaceuticals, Inc. Paid as CEO
Kenneth C. Frazier
71 2022
4 years
Independent None stated None stated Not stated
Robert Huffines
60 2023
3 years
Independent
Audit Committee
Insulet Corporation, Becton, Dickinson and Company Not stated
David Meline
68 Not stated Independent
Audit Committee · Chair
Lonza Group AG, HP Inc., ABB Ltd. Not stated
Ma. Fatima D. Francisco Joined Jun 15, 2026
- - -
Compensation Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. Eikon Therapeutics, Inc. has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support